Skip Nav Destination
Issues
1 May 2007
-
Cover Image
Cover Image
Treatment of established Colon 26 tumors with targeted (TNT-3/CD137L) or untargeted (Fc-CD137L) fusion proteins or the agonist antibody 2A directed against murine CD137 producesCD8+ T-cell–dependent regression and complete remission in mice. Morphologic and immunohistochemical studies showed that both CD137L fusion proteins induced massive central necrosis and infiltration of granzyme B-positive cells in necrotic areas and viable peripheral regions of tumors. From these studies, it was determined that both targeted and untargeted CD137L fusion proteins demonstrated effective antitumor activity, providing convincing evidence that CD137L costimulation is a viable strategy for successful tumor immunotherapy. For further details, please see Zhang et al.on page 2758 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editorials
Molecular Pathways
Human Cancer Biology
Epigenetic Modifications of RASSF1A Gene through Chromatin Remodeling in Prostate Cancer
Ken Kawamoto; Steven T. Okino; Robert F. Place; Shinji Urakami; Hiroshi Hirata; Nobuyuki Kikuno; Toshifumi Kawakami; Yuichiro Tanaka; Deepa Pookot; Zhong Chen; Shahana Majid; Hideki Enokida; Masayuki Nakagawa; Rajvir Dahiya
The Folate Receptor α Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate
Rui Yang; E. Anders Kolb; Jing Qin; Alexander Chou; Rebecca Sowers; Bang Hoang; John H. Healey; Andrew G. Huvos; Paul A. Meyers; Richard Gorlick
Expression of a Peroxisome Proliferator-Activated Receptor γ1 Splice Variant that Was Identified in Human Lung Cancers Suppresses Cell Death Induced by Cisplatin and Oxidative Stress
Hyo Jung Kim; Jin-Yong Hwang; Hyun Jun Kim; Wan Sung Choi; Jae Heun Lee; Hye Jung Kim; Ki Churl Chang; Toru Nishinaka; Chihiro Yabe-Nishimura; Han Geuk Seo
Imaging, Diagnosis, Prognosis
Relationship between Survival and Edema in Malignant Gliomas: Role of Vascular Endothelial Growth Factor and Neuronal Pentraxin 2
Marc R.J. Carlson; Whitney B. Pope; Steve Horvath; Jerome G. Braunstein; Phioanh Nghiemphu; Cho-Lea Tso; Ingo Mellinghoff; Albert Lai; Linda M. Liau; Paul S. Mischel; Jun Dong; Stanley F. Nelson; Timothy F. Cloughesy
Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival
Marica Eoli; Francesca Menghi; Maria Grazia Bruzzone; Tiziana De Simone; Lorella Valletta; Bianca Pollo; Lorena Bissola; Antonio Silvani; Donatella Bianchessi; Ludovico D'Incerti; Graziella Filippini; Giovanni Broggi; Amerigo Boiardi; Gaetano Finocchiaro
MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population
Gangqiao Zhou; Yun Zhai; Ying Cui; Xiumei Zhang; Xiaojia Dong; Hao Yang; Ying He; Kaitai Yao; Hongxing Zhang; Lianteng Zhi; Xiaoyan Yuan; Wei Qiu; Xiaoai Zhang; Yan Shen; Boqing Qiang; Fuchu He
Cancer Therapy: Clinical
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Anat Norden-Zfoni; Jayesh Desai; Judith Manola; Paul Beaudry; Jeremy Force; Robert Maki; Judah Folkman; Carlo Bello; Charles Baum; Sam E. DePrimo; David R. Shalinsky; Goerge D. Demetri; John V. Heymach
Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91
Stefan Rutkowski; André von Bueren; Katja von Hoff; Wolfgang Hartmann; Tarek Shalaby; Frank Deinlein; Monika Warmuth-Metz; Niels Soerensen; Angela Emser; Udo Bode; Uwe Mittler; Christian Urban; Martin Benesch; Rolf D. Kortmann; Paul G. Schlegel; Joachim Kuehl; Torsten Pietsch; Michael Grotzer
Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
Chris H. Takimoto; Lisa A. Hammond-Thelin; Jane E. Latz; Leonardo Forero; Muralidhar Beeram; Bahram Forouzesh; Johann de Bono; Anthony W. Tolcher; Amita Patnaik; Pamela Monroe; Leslie Wood; Karen B. Schneck; Romnee Clark; Eric K. Rowinsky
Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non–Small Cell Lung Cancer
Alex A. Adjei; Julian R. Molina; Sumithra J. Mandrekar; Randolph Marks; Joel R. Reid; Gary Croghan; Lorelei J. Hanson; James R. Jett; Chenghua Xia; Chetan Lathia; Ronit Simantov
A Phase 1 Study of Pralatrexate in Combination with Paclitaxel or Docetaxel in Patients with Advanced Solid Tumors
Christopher G. Azzoli; Lee M. Krug; Jorge Gomez; Vincent A. Miller; Mark G. Kris; Michelle S. Ginsberg; Roxanne Henry; Jessica Jones; Leslie Tyson; Megan Dunne; Barbara Pizzo; Amy Farmer; Ennapadam Venkatraman; Robert Steffen; F.M. Sirotnak
CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients
Sonia A. Perez; Michael V. Karamouzis; Dimosthenes V. Skarlos; Alexandros Ardavanis; Nectaria N. Sotiriadou; Eleni G. Iliopoulou; Maria L. Salagianni; George Orphanos; Constantin N. Baxevanis; Gerasimos Rigatos; Michael Papamichail
Cancer Therapy: Preclinical
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
Cherrie K. Donawho; Yan Luo; Yanping Luo; Thomas D. Penning; Joy L. Bauch; Jennifer J. Bouska; Velitchka D. Bontcheva-Diaz; Bryan F. Cox; Theodore L. DeWeese; Larry E. Dillehay; Debra C. Ferguson; Nayereh S. Ghoreishi-Haack; David R. Grimm; Ran Guan; Edward K. Han; Rhonda R. Holley-Shanks; Boris Hristov; Kenneth B. Idler; Ken Jarvis; Eric F. Johnson; Lawrence R. Kleinberg; Vered Klinghofer; Loren M. Lasko; Xuesong Liu; Kennan C. Marsh; Thomas P. McGonigal; Jonathan A. Meulbroek; Amanda M. Olson; Joann P. Palma; Luis E. Rodriguez; Yan Shi; Jason A. Stavropoulos; Alan C. Tsurutani; Gui-Dong Zhu; Saul H. Rosenberg; Vincent L. Giranda; David J. Frost
SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas
Monica Fedele; Ivana De Martino; Rosario Pivonello; Andrea Ciarmiello; M. Laura Del Basso De Caro; Rosa Visone; Dario Palmieri; Giovanna M. Pierantoni; Claudio Arra; Herbert A. Schmid; Leo Hofland; Gaetano Lombardi; Annamaria Colao; Alfredo Fusco
Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of Melanoma
Yumiko Azuma; Yuji Ishikawa; Shigeto Kawai; Toshiaki Tsunenari; Hiroyuki Tsunoda; Tomoyuki Igawa; Shin-ichiro Iida; Masahiko Nanami; Masami Suzuki; Reiko F. Irie; Masayuki Tsuchiya; Hisafumi Yamada-Okabe
A Mosaic Fiber Adenovirus Serotype 5 Vector Containing Reovirus σ1 and Adenovirus Serotype 3 Knob Fibers Increases Transduction in an Ovarian Cancer Ex vivo System via a Coxsackie and Adenovirus Receptor–Independent Pathway
Yuko Tsuruta; Larisa Pereboeva; Joel N. Glasgow; Daniel T. Rein; Yosuke Kawakami; Ronald D. Alvarez; Rodney P. Rocconi; Gene P. Siegal; Paul Dent; Paul B. Fisher; David T. Curiel
Akt/cAMP-Responsive Element Binding Protein/Cyclin D1 Network: A Novel Target for Prostate Cancer Inhibition in Transgenic Adenocarcinoma of Mouse Prostate Model Mediated by Nexrutine, a Phellodendron Amurense Bark Extract
Addanki P. Kumar; Shylesh Bhaskaran; Manonmani Ganapathy; Katherine Crosby; Michael D. Davis; Peter Kochunov; John Schoolfield; I-Tien Yeh; Dean A. Troyer; Rita Ghosh
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds